MA40574A - Traitement de maladies fibrotiques - Google Patents
Traitement de maladies fibrotiquesInfo
- Publication number
- MA40574A MA40574A MA040574A MA40574A MA40574A MA 40574 A MA40574 A MA 40574A MA 040574 A MA040574 A MA 040574A MA 40574 A MA40574 A MA 40574A MA 40574 A MA40574 A MA 40574A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- fibrotic diseases
- rspo
- treating
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
La présente invention concerne des antagonistes de rspo et lgr, ainsi que des méthodes d'utilisation des antagonistes de lgr et rspo pour le traitement ou la prévention de maladies fibrotiques. La présente invention concerne des méthodes de traitement d'une maladie fibrotique chez le patient, les méthodes comprenant l'administration au patient d'une quantité thérapeutiquement efficace d'un antagoniste de rpso et/ou de lgr, tel qu'un anticorps anti-rspo, un anticorps anti-lgr ou un récepteur soluble de lgr
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462051026P | 2014-09-16 | 2014-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40574A true MA40574A (fr) | 2016-03-24 |
Family
ID=55533756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040574A MA40574A (fr) | 2014-09-16 | 2015-09-15 | Traitement de maladies fibrotiques |
Country Status (9)
Country | Link |
---|---|
US (1) | US10064937B2 (fr) |
EP (1) | EP3193935A4 (fr) |
JP (1) | JP2017528523A (fr) |
CN (1) | CN106687137A (fr) |
AU (1) | AU2015317986A1 (fr) |
CA (1) | CA2961374A1 (fr) |
MA (1) | MA40574A (fr) |
TW (1) | TW201628648A (fr) |
WO (1) | WO2016044295A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110546270A (zh) * | 2017-07-18 | 2019-12-06 | 株式会社资生堂 | 抗衰老物质的筛选方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070124581A1 (en) | 1992-05-17 | 2007-05-31 | Reena Khare | Cell adhesion and extracellular matrix proteins |
CA2288343A1 (fr) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Proteines secretees et polynucleotides les codant |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
JP2001517441A (ja) | 1997-09-24 | 2001-10-09 | メルク エンド カムパニー インコーポレーテッド | Gタンパク質共役糖タンパク質ホルモン受容体hg38 |
US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
DE69941330D1 (de) | 1998-03-26 | 2009-10-08 | Univ R | Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
US20030166047A1 (en) | 1999-05-06 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Lgr6 nucleic acids and uses thereof |
WO2001007611A2 (fr) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Nouveaux polynucleotides et technique d'utilisation de ceux-ci |
US6824973B2 (en) | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
WO2001057190A2 (fr) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Acides nucleiques et polypeptides |
AU5301201A (en) | 2000-03-31 | 2001-10-15 | Gen Hospital Corp | Methods of modulating hair growth |
CA2405104A1 (fr) | 2000-04-05 | 2001-10-18 | Kirin Beer Kabushiki Kaisha | Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches |
EP1156062A1 (fr) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Peptides/protéines immunomodulants et liants à un antigène du CMH classe II humain |
AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US20030139341A1 (en) | 2000-05-30 | 2003-07-24 | Shyam Ramakrishnan | Regulation of human lgr4-like g protein -coupled receptor |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6768004B2 (en) | 2001-01-11 | 2004-07-27 | Mueller Sybille | Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies |
US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
US20030032034A1 (en) | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20100292155A1 (en) | 2001-03-05 | 2010-11-18 | Arca Biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
JP4251983B2 (ja) | 2001-06-11 | 2009-04-08 | 協和発酵キリン株式会社 | 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするdna |
WO2002102854A2 (fr) | 2001-06-20 | 2002-12-27 | Morphosys Ag | Anticorps bloquant l'activation d'une tyrosine kinase de type proteine receptrice, procedes permettant l'identification de cet anticorps et utilisations de celui-ci |
US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
CA2458818A1 (fr) | 2001-08-30 | 2003-04-10 | Nuvelo, Inc. | Procedes et materiaux relatifs aux polynucleotides et polypeptides de type facteur de croissance de cellules souches |
WO2003029437A2 (fr) | 2001-10-03 | 2003-04-10 | Incyte Genomics Inc. | Proteines secretees |
US20040197778A1 (en) | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
JP2005511754A (ja) | 2001-12-07 | 2005-04-28 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 乳癌幹細胞の予測的同定および特徴づけ |
EP1504099A4 (fr) | 2001-12-10 | 2006-05-10 | Nuvelo Inc | Nouveaux acides nucleiques et polypeptides |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
US7439332B2 (en) | 2002-04-26 | 2008-10-21 | Kirin Pharma Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells |
EP1380644A1 (fr) | 2002-07-08 | 2004-01-14 | Kylix B.V. | Utilisation de gènes cible spécifiques de TCF pour identifier des medicaments pour le traitement du cancer, en particulier le cancer colorectal, dans lequel TCF/beta-catenin/WNT signalisation joue un rôle central |
WO2004074436A2 (fr) | 2003-02-19 | 2004-09-02 | Incyte Corporation | Procede d'utilisation d'un gpcr pour diagnostiquer et traiter le cancer du colon et du poumon |
US20050003405A1 (en) | 2003-04-30 | 2005-01-06 | Hua-Chien Chen | Treatment and diagnostics of cancer |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
WO2005110009A2 (fr) | 2003-07-22 | 2005-11-24 | Immunex Corporation | Compositions et methodes relatives aux tsp-30a, b, c et d |
DE10339820A1 (de) | 2003-08-22 | 2005-03-17 | Hinzmann, Bernd, Dr. | Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
EP2093298A3 (fr) | 2003-10-10 | 2009-09-23 | Deutsches Krebsforschungszentrum | Compositions pour le diagnostic et la thérapie des maladies associées à l'expression aberrante de futrines (R-Spondins) |
WO2005040828A2 (fr) | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49) |
RU2343158C2 (ru) | 2004-01-27 | 2009-01-10 | Ньювело, Инк. | Желудочно-кишечный пролиферативный фактор и его применения |
AU2005209909B8 (en) | 2004-02-03 | 2009-01-15 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US7572456B2 (en) | 2004-09-13 | 2009-08-11 | Macrogenics, Inc. | Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof |
CA2591665C (fr) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes |
US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
WO2006110585A2 (fr) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Genes lies au cancer (prlr) |
US20090311243A1 (en) * | 2005-05-30 | 2009-12-17 | Astrazeneca Ab | Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis |
EP1917022A2 (fr) | 2005-07-26 | 2008-05-07 | Kirin Pharma Kabushiki Kaisha | Agents anti-tumeur comprenant des r-spondines |
WO2007030290A2 (fr) | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Ligands cristine/r-spondine actifs dans la voie de signalisation wnt et methodes, compositions et kits associes |
CA2623413A1 (fr) | 2005-10-07 | 2007-09-07 | Nuvelo, Inc. | Scfa1, proteine du type facteur des cellules souches et utilisations de celle-ci |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP2380908A1 (fr) | 2006-06-02 | 2011-10-26 | Aveo Pharmaceuticals, Inc. | Protéines de liaison au facteur de croissance des cellules hépatiques (hgf) |
WO2007143090A2 (fr) | 2006-06-02 | 2007-12-13 | Aveo Pharmaceuticals, Inc. | Protéines de liaison au facteur de croissance des cellules hépatiques (hgf) |
KR101528939B1 (ko) | 2006-07-18 | 2015-06-15 | 사노피 | 암 치료를 위한 epha2에 대한 길항제 항체 |
JP2008044926A (ja) | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
SI2066694T1 (sl) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za diagnosticiranje in zdravljenje raka |
HUE027179T2 (en) | 2006-10-20 | 2016-10-28 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Angiogenesis and vasculogenesis modulator for Rspond |
WO2008075796A1 (fr) | 2006-12-21 | 2008-06-26 | Kyowa Hakko Kirin Co., Ltd. | Agent pour encourager la récupération après une déplétion de globule sanguin |
WO2008088524A2 (fr) | 2006-12-28 | 2008-07-24 | Nuvelo, Inc. | Protéine r-spondine 1 à carence en domaines de thrombospondine utilisee en tant que facteur de prolifération épithéliale du tractus gastro-intestinal |
US20100330089A1 (en) | 2007-06-12 | 2010-12-30 | Wyeth | Anti-cd20 therapeutic compositions and methods |
HUE027154T2 (en) * | 2007-07-02 | 2016-08-29 | Oncomed Pharm Inc | Preparations and procedures for the treatment and diagnosis of cancer |
US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
EP2188630A4 (fr) | 2007-10-02 | 2010-11-03 | Univ Rochester | Méthodes et compositions associées aux réponses synergiques aux mutations oncogènes |
CA2705509A1 (fr) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | Diagnostic et traitement du cancer a l'aide d'un anticorps anti-gpr49 |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
WO2010016766A2 (fr) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène |
CN103408664B (zh) | 2008-10-31 | 2015-11-25 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
WO2010121923A1 (fr) | 2009-04-15 | 2010-10-28 | Deutsches Krebsforschungszentrum | Inhibition de la rspondine-3 dans des troubles osseux |
WO2010129284A1 (fr) | 2009-04-27 | 2010-11-11 | The Trustees Of The University Of Pennsylvania | Inhibition de la croissance de follicule pileux par l'inhibiteur de wnt dkk1 |
JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
US20120114646A1 (en) | 2009-06-18 | 2012-05-10 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
WO2011009090A1 (fr) | 2009-07-16 | 2011-01-20 | Xoma Technology Ltd. | Anticorps dirigés contre lantigène de poids moléculaire élevé associé au mélanome |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
EP2515933B1 (fr) | 2009-12-23 | 2016-03-30 | Deutsches Krebsforschungszentrum | Recepteurs de rspo2 et rspo3 |
WO2011085289A1 (fr) | 2010-01-11 | 2011-07-14 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Production d'un anticorps monoclonal thérapeutique contre le virus west nile chez les plantes |
WO2011140441A2 (fr) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Procédés et systèmes de conversion de cellules précurseurs en tissus intestinaux par différenciation dirigée |
JP5889912B2 (ja) * | 2010-11-17 | 2016-03-22 | ジェネンテック, インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
US20150024952A1 (en) | 2010-12-28 | 2015-01-22 | Arlet Alarcon | Molecular profiling for cancer |
GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
AU2012248158C1 (en) | 2011-04-28 | 2017-02-02 | Sbi Biotech Co., Ltd. | Anti-human receptor-type protein tyrosine phosphatase sigma antibody |
US10233502B2 (en) | 2011-06-22 | 2019-03-19 | Indiana University Research And Technology Corporation | Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer |
KR20140048276A (ko) | 2011-07-15 | 2014-04-23 | 온코메드 파마슈티칼스, 인크. | Rspo 결합제 및 이의 용도 |
CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
AU2013216753B2 (en) | 2012-02-11 | 2017-09-21 | Genentech, Inc. | R-spondin translocations and methods using the same |
WO2013144672A1 (fr) * | 2012-03-30 | 2013-10-03 | Société De Développement Et De Recherche Industrielle | Procédé et kit destinés à la classification et au pronostic de lésions |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
KR20150036603A (ko) | 2012-07-13 | 2015-04-07 | 온코메드 파마슈티칼스, 인크. | Rspo3 결합제 및 그의 용도 |
CA2905830C (fr) | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Derives de quinazoline et de naphtyridine utiles dans le traitement du cancer |
EP3006942A4 (fr) | 2013-05-30 | 2016-11-30 | Order Made Medical Res Inc | Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer |
RU2016114074A (ru) | 2013-10-18 | 2017-11-23 | Дженентек, Инк. | Анти-rspo антитела и способы применения |
US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
-
2015
- 2015-09-15 TW TW104130440A patent/TW201628648A/zh unknown
- 2015-09-15 WO PCT/US2015/050225 patent/WO2016044295A1/fr active Application Filing
- 2015-09-15 EP EP15841837.6A patent/EP3193935A4/fr not_active Withdrawn
- 2015-09-15 JP JP2017533740A patent/JP2017528523A/ja active Pending
- 2015-09-15 CA CA2961374A patent/CA2961374A1/fr not_active Abandoned
- 2015-09-15 CN CN201580049993.4A patent/CN106687137A/zh active Pending
- 2015-09-15 MA MA040574A patent/MA40574A/fr unknown
- 2015-09-15 AU AU2015317986A patent/AU2015317986A1/en not_active Abandoned
- 2015-09-15 US US14/855,053 patent/US10064937B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10064937B2 (en) | 2018-09-04 |
TW201628648A (zh) | 2016-08-16 |
EP3193935A4 (fr) | 2018-03-21 |
AU2015317986A1 (en) | 2017-03-09 |
EP3193935A1 (fr) | 2017-07-26 |
US20160166684A1 (en) | 2016-06-16 |
WO2016044295A1 (fr) | 2016-03-24 |
CA2961374A1 (fr) | 2016-03-24 |
JP2017528523A (ja) | 2017-09-28 |
CN106687137A (zh) | 2017-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264049A (en) | Compounds, preparations and methods for treating the disease | |
IL252159B (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
IL264156A (en) | Compounds, preparations and methods for treating the disease | |
GB2544906B (en) | Devices for treating vestibular and other medical impairments. | |
MX2017002271A (es) | Composiciones y metodos para el tratamiento de trastornos neurologicos. | |
MD20170032A2 (ro) | Anticorpi anti-TIGIT | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2017003797A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
HK1254432A1 (zh) | 用於治療纖維性疾病的方法和組合物 | |
ZA201608281B (en) | Ppar compounds for use in the treatment of fibrotic diseases. | |
ZA201804950B (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
MX2017002489A (es) | Agentes terapeuticos humanos. | |
MX2017000306A (es) | Metodos para tratar hipotension. | |
IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
IL269083A (en) | Methods for the prevention and treatment of heart diseases | |
PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
IL271728A (en) | Materials, uses and treatment methods | |
IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
IL252904A0 (en) | Methods and factors for treating diseases | |
MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
MX2019000677A (es) | Células miméticas de células b. | |
MA40574A (fr) | Traitement de maladies fibrotiques | |
EP3481372A4 (fr) | Compositions et méthodes de traitement d'une maladie cardiaque | |
SG11201701618SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |